Sun Pharma Advanced Research Co (NSE:SPARC) EPS without NRI: ₹48.12 (TTM As of Mar. 2026)


NSE:SPARC Sun Pharma Advanced Research Co Ltd NSE:SPARC
67 GF Score
Price ₹264.60
GF Value ₹4,526.00
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Sun Pharma Advanced Research Co EPS without NRI?

Sun Pharma Advanced Research Co NSE:SPARC -4.67% 67 EPS without NRI is ₹48.12 as of Mar. 2026. GuruFocus rates NSE:SPARC with a GF Score™ of 67/100 and a GF Value™ of ₹4,526.00 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 786 Drug Manufacturers companies, Sun Pharma Advanced Research Co ranks worse than 127226.34% on this metric.

Sun Pharma Advanced Research Co's earnings per share without non-recurring items for the three months ended in Mar. 2026 was ₹54.27. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was ₹48.12.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Sun Pharma Advanced Research Co's EPS without NRI or its related term are showing as below:

During the past 13 years, Sun Pharma Advanced Research Co's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 21.00% per year. The lowest was -99.40% per year. And the median was -22.40% per year.

NSE:SPARC's 3-Year EPS without NRI Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 9.6
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Sun Pharma Advanced Research Co's EPS (Diluted) for the three months ended in Mar. 2026 was ₹54.27. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹47.85.

Sun Pharma Advanced Research Co's EPS (Basic) for the three months ended in Mar. 2026 was ₹54.27. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹47.85.


Sun Pharma Advanced Research Co  (NSE:SPARC) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Sun Pharma Advanced Research Co EPS without NRI Related Terms


Sun Pharma Advanced Research Co EPS without NRI Historical Data

* Premium members only.

The historical data trend for Sun Pharma Advanced Research Co's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sun Pharma Advanced Research Co EPS without NRI Chart

Sun Pharma Advanced Research Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.93 -7.93 -12.01 -10.55 48.09

Sun Pharma Advanced Research Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.84 -1.60 -2.34 -2.21 54.27

NSE:SPARC vs ZTS, UTHR: EPS without NRI Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sun Pharma Advanced Research Co's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sun Pharma Advanced Research Co PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sun Pharma Advanced Research Co's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Sun Pharma Advanced Research Co's PE Ratio without NRI falls into.


NSE:SPARC
67GF Score
Sun Pharma Advanced Research Co Ltd NSE:SPARC
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sun Pharma Advanced Research Co EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹48.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of ₹48.12 mean?
Sun Pharma Advanced Research Co (NSE:SPARC) has a EPS without NRI of ₹48.12 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Sun Pharma Advanced Research Co and its competitors. According to the industry distribution chart, Sun Pharma Advanced Research Co ranks #999999 out of 786 companies in the Drug Manufacturers industry.
Is Sun Pharma Advanced Research Co's EPS without NRI too high?
Sun Pharma Advanced Research Co's current EPS without NRI is ₹48.12. Based on the distribution chart, Sun Pharma Advanced Research Co ranks #999999 out of 786 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sun Pharma Advanced Research Co has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sun Pharma Advanced Research Co's EPS without NRI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sun Pharma Advanced Research Co ranks #999999 out of 786 companies for EPS without NRI. This places Sun Pharma Advanced Research Co in the lower half of its industry. The industry median EPS without NRI is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.60, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Sun Pharma Advanced Research Co and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sun Pharma Advanced Research Co's current EPS without NRI is ₹48.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sun Pharma Advanced Research Co stock overvalued right now?
Based on GuruFocus' analysis, Sun Pharma Advanced Research Co (NSE:SPARC) is currently considered Possible Value Trap. The stock's GF Value™ is ₹4,526.00, compared to a current price of ₹264.60 — trading 94.2% below its estimated fair value. The current EPS without NRI is ₹48.12. Sun Pharma Advanced Research Co's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Sun Pharma Advanced Research Co (NSE:SPARC), the current EPS without NRI is ₹48.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sun Pharma Advanced Research Co (NSE:SPARC) Overvalued in 2026?

Based on GuruFocus' analysis, Sun Pharma Advanced Research Co stock appears to be undervalued. The current stock price of ₹264.60 is trading 94.2% below its estimated GF Value™ of ₹4,526.00. GuruFocus considers Sun Pharma Advanced Research Co to be Possible Value Trap.

Key valuation signals for NSE:SPARC:

  • EPS without NRI: ₹48.12
  • GF Value™: ₹4,526.00 vs. price of ₹264.60 (94.2% below fair value)
  • GF Score™: 67/100 with 7 warning signs

No single metric tells the full story. See the NSE:SPARC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sun Pharma Advanced Research Co Business Description

Other Exchanges 532872:India
Address Off Mahakali Caves Road, 17-B, Mahal Industrial Estate, Andheri (East), Mumbai, MH, IND, 400093
Sun Pharma Advanced Research Co Ltd is an Indian specialty and generic drug manufacturing company. The company has identified pharmaceuticals research and development as its only reportable segment. The company is focused on drug discovery in focused therapy areas such as cancer and anti-inflammatory treatments. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. It derives maximum revenue from India and also has its presence in other countries.
67GF Score

Get the complete analysis for NSE:SPARC

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹264.60
Price
₹4,526.00
GF Value